Yazar "Taşdemir M." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Yayın
    Botulinum toxin in the treatment of trigeminal neuralgia: 6-Month follow-up
    (Lippincott Williams and Wilkins, 2017) Türk Börü Ü.; Duman A.; Bölük C.; Coşkun Duman S.; Taşdemir M.
    Background: Botulinum toxin type-A (BTX-A) has been successfully utilized to treat trigeminal neuralgia. In this study, through the use of a new technique, the efficacy of the injection of BTX-A to the maxillary and mandibular nerves was evaluated. Methods: A total of 27 patients were injected with 100 Units of BTX-A to the maxillary and mandibular nerves. Visual analogue scale score and pain frequency were assessed before treatment and at the first week, second month, and sixth month after treatment. Patients with ?50% reduction in mean pain score at the second and sixth month were defined as responders. Results: A total of 27 patients were included in the study. BTX-A significantly reduced pain intensity and pain attack frequency at the first week, second month, and sixth month after treatment. At the second month, 74.1% of patients, at the sixth month, 88.9% of patients responded to treatment. Forty-four percent of patients did not experience any pain at the sixth month. The mean recurrence period was 87.7±20.4. BTX-A was well tolerated and showed few treatment-related adverse events. Conclusion: Injection to the maxillary and mandibular roots seems to be a highly effective method. In the event of recurrence, after each injection, the pain severity and attack frequency decreased. Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.
  • Küçük Resim Yok
    Yayın
    Multiple sclerosis prevalence study the comparison of 3 coastal cities, located in the black sea and mediterranean regions of Turkey
    (Lippincott Williams and Wilkins, 2018) Börü Ü.T.; Duman A.; Kulualp A.Ş.; Güler N.; Taşdemir M.; Yılmaz Ü.; Alp R.; Bölük C.
    The prevalence of multiple sclerosis (MS) has significantly increased all over the world. Recent studies have shown that Turkey has quite a high prevalence. The aim of this study is to estimate prevalence in the Mediterranean and Black Sea regions of Turkey and to compare the results. This study was designed as a door to door survey in 3 cities. One is located in the Mediterranean region (South), 2 are located in the Black Sea region (North). A previous validated form was used for screening in the field. The patients were examined first in the field, then in the regional health facility. McDonald criteria were used for the diagnosis. In total, 26 patients were diagnosed with MS. The prevalence was found to be 18.6/100,000 in Artvin (Black Sea region), 55.5/100,000 in Ordu, (Black Sea region), 52.00/100,000 in Gazipaşa (Mediterranean region). The female/male ratio was 2.25. This study is the first prevalence study which was conducted in the Mediterranean City (South) of Turkey. The prevalence rate was found to be higher than expected in the Mediterranean city of Gazipaşa. The results showed that the prevalence varies from region to region. Latitude difference was not observed. Copyright © 2018 the Author(s).